-
Innovation Ranking
NewInnovation Ranking – Collegium Pharmaceutical Inc
Collegium Pharmaceutical Inc (Collegium) is a specialty pharmaceutical company that focuses on the development and commercialization of innovative drugs for treating patients suffering from pain. It develops products based on its DETERx platform technology. DETERx offers extended-release drug delivery, while protecting against common methods of abuse and tampering. The company's lead product, Xtampza ER is designed to provide adequate pain control. Its other products include Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral...
-
Company Insights
Innovation and Patenting activity of Collegium Pharmaceutical Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Collegium Pharmaceutical Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
Attention Deficit Hyperactivity Disorder (ADHD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Attention Deficit Hyperactivity Disorder (ADHD) - Drugs In Development, 2023’, provides an overview of the Attention Deficit Hyperactivity Disorder (ADHD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Hydrocodone ER in Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Hydrocodone ER in Pain report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Hydrocodone ER in PainDrug Details:Hydrocodone ER is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – STK-012 in Metastatic Melanoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. STK-012 in Metastatic Melanoma Drug Details: STK-012 is under development for the treatment of solid...
-
Product Insights
Hydrogels Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Hydrogels Pipeline Market Report Overview Hydrogels include dressings that consist of 96% water with a matrix of insoluble polymers embedded in it. The former helps to maintain a moist wound environment while the latter facilitates absorption of wound exudates. These dressings are available in the form of tubes and sheets and both of them are tracked under this segment. Hydrogels are segmented into antimicrobial and non-antimicrobial hydrogel dressings. The Hydrogels pipeline market research report provides comprehensive information about the Hydrogels...
-
Company Profile
Collegium Pharmaceutical Inc – Company Profile
Collegium Pharmaceutical Inc (Collegium) is a specialty pharmaceutical company that focuses on the development and commercialization of innovative drugs for treating patients suffering from pain. It develops products based on its DETERx platform technology. DETERx offers extended-release drug delivery, while protecting against common methods of abuse and tampering. The company's lead product, Xtampza ER is designed to provide adequate pain control. Its other products include Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral...
Add to Basket -
Product Insights
Net Present Value Model: Elyxyb
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Elyxyb Drug Details Celecoxib (Elyxyb) is...
-
Product Insights
Net Present Value Model: Xtampza ER
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Xtampza ER Drug Details Oxycodone (Oxycodone...
-
Product Insights
Net Present Value Model: Belbuca
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Belbuca Drug Details Buprenorphine Hydrochloride (Belbuca)...